ScholarLens Back to search
2004•Journal of Practical Diagnosis and TherapyRequires access

Study on vindesine in treatment of 78 cases of advanced non-small cell lung cancer by combined chemotherapy

Jiang Shuguan

Open publisher page 0 citations

Abstract

Objective To evaluate the efficacy of vindesine in non-small cell lung cancer (NSCLC) patients and to observed the side effects of vindesine. Methods One hundred forty-two patients with advanced NSCLC(stage Ⅲb or Ⅳ)were divided into 2 groups randomly to give CAP+ vindesine(78 cases)or CAP(64 cases)regimens. The characteristics were well-balanced between the 2 groups with regards to sex, age, performance status, stage, histology and previous chemotherapy. Results The effective rate(41.9%)in the CAP+ vindesine group was higher than that (16.7) in CAP group. The main side effects of vindesine group were myelosuppression, perpheral neuropathy and mild phlebitis. The dose limiting toxicity of CAP+ vindesine regimen was myelosuppression. Conclusion The efficacy of vindesine to NSCLC is confirmed. There was some synergy when vindesine is combined with CAP regimen. The side effects are tolerable.

About this research paper

What this paper is about

Objective To evaluate the efficacy of vindesine in non-small cell lung cancer (NSCLC) patients and to observed the side effects of vindesine. Methods One hundred forty-two patients with advanced NSCLC(stage Ⅲb or Ⅳ)were divided into 2 groups randomly to give CAP+ vindesine(78 cases)or CAP(64 cases)regimens. The characteristics were well-balanced between the 2 groups with regards to sex, age, performance status, stage, histology and previous chemotherapy. Results The effective rate(41.9%)in the CAP+ vindesine group was higher than that (16.7) in CAP group. The main side effects of vindesine group were myelosuppression, perpheral neuropathy and mild phlebitis. The dose limiting toxicity of CAP+ vindesine regimen was myelosuppression. Conclusion The efficacy of vindesine to NSCLC is confirmed. There was some synergy when vindesine is combined with CAP regimen. The side effects are tolerable.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the efficacy of vindesine in non-small cell lung cancer (NSCLC) patients and to observed the side effects of vindesine. Methods One hundred forty-two patients with advanced NSCLC(stage Ⅲb or Ⅳ)were divided into 2 groups randomly to give CAP+ vindesine(78 cases)or CAP(64 cases)regimens. The characteristics were well-balanced between the 2 groups with regards to sex, age, performance status, stage, histology and previous chemotherapy. Results The effective rate(41.9%)in the CAP+ vindesine group was higher than that (16.7) in CAP group. The main side effects of vindesine group were myelosuppression, perpheral neuropathy and mild phlebitis. The dose limiting toxicity of CAP+ vindesine regimen was myelosuppression. Conclusion The efficacy of vindesine to NSCLC is confirmed. There was some synergy when vindesine is combined with CAP regimen. The side effects are tolerable.

Key concepts: Vindesine, Medicine, Lung cancer, Regimen, Chemotherapy, Internal medicine, Gastroenterology, Side effect (computer science)

Back to paper searchBrowse research topicsOriginal source
Study on vindesine in treatment of 78 cases of advanced non-small cell lung cancer by combined chemotherapy — Research Paper | ScholarLens